Suppliers and packagers for generic pharmaceutical drug: ENALAPRILAT

ENALAPRILAT

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Dr Reddys	ENALAPRILAT	enalaprilat	INJECTABLE;INJECTION	075578	ANDA	Dr. Reddys Laboratories Inc	43598-078-58	10 VIAL in 1 CARTON (43598-078-58) / 1 mL in 1 VIAL (43598-078-11)	2023-06-06
Dr Reddys	ENALAPRILAT	enalaprilat	INJECTABLE;INJECTION	075578	ANDA	Dr. Reddys Laboratories Inc	43598-169-58	10 VIAL in 1 CARTON (43598-169-58) / 2 mL in 1 VIAL (43598-169-11)	2023-06-06
Hikma Farmaceutica	ENALAPRILAT	enalaprilat	INJECTABLE;INJECTION	078687	ANDA	Hikma Pharmaceuticals USA Inc.	0143-9786-10	10 VIAL in 1 CARTON (0143-9786-10) / 2 mL in 1 VIAL (0143-9786-01)	2008-12-23
Hikma Farmaceutica	ENALAPRILAT	enalaprilat	INJECTABLE;INJECTION	078687	ANDA	Hikma Pharmaceuticals USA Inc.	0143-9787-10	10 VIAL in 1 CARTON (0143-9787-10) / 1 mL in 1 VIAL (0143-9787-01)	2008-12-23
Hikma Farmaceutica	ENALAPRILAT	enalaprilat	INJECTABLE;INJECTION	078687	ANDA	HF Acquisition Co LLC, DBA HealthFirst	51662-1477-1	1 mL in 1 VIAL (51662-1477-1)	2020-02-01

Enalaprilat Drug Supply Chain: Key Manufacturers and Intellectual Property Landscape

Last updated: February 19, 2026

This report analyzes the current landscape of enalaprilat drug supply, identifying key manufacturers of active pharmaceutical ingredients (APIs) and finished dosage forms. It also examines the intellectual property (IP) protections surrounding enalaprilat, including patent expiry dates and potential generic entry.

Who Manufactures Enalaprilat API?

The global supply of enalaprilat API is concentrated among a limited number of manufacturers, primarily located in India and China. These companies operate under strict regulatory oversight from agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Key API manufacturers include:

• Divi's Laboratories Limited: A prominent Indian API producer with a significant portfolio of cardiovascular drugs. Divi's has a history of supplying enalaprilat to global markets.
• Laurus Labs Limited: Another major Indian pharmaceutical company specializing in APIs and finished dosage forms. Laurus Labs is known for its backward integration and cost-efficient manufacturing.
• Aarti Industries Limited: An established Indian chemical and pharmaceutical manufacturer with a broad range of APIs, including those for cardiovascular therapies.
• Zhejiang Huahai Pharmaceutical Co., Ltd.: A leading Chinese pharmaceutical company that manufactures a wide array of APIs and intermediates. Huahai is a significant player in the global supply chain for angiotensin-converting enzyme (ACE) inhibitors.
• Anand Synthetic Pvt. Ltd.: An Indian company that supplies various pharmaceutical intermediates and APIs, including those for enalaprilat.

These manufacturers adhere to Good Manufacturing Practices (GMP) and often hold Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP) or Drug Master Files (DMFs) with regulatory authorities, facilitating their use in regulated markets.

What are the Major Suppliers of Finished Enalaprilat Dosage Forms?

The market for finished enalaprilat products is characterized by both branded and generic formulations. Branded products are typically manufactured by originator companies or their licensed partners, while generic versions are produced by multiple pharmaceutical firms worldwide.

Major suppliers of finished enalaprilat dosage forms include:

• Merck & Co., Inc. (as the originator of Vasotec®): While enalaprilat is administered intravenously, its oral prodrug, enalapril maleate, is widely marketed as Vasotec®. Merck continues to hold significant market share for its branded products.
• Teva Pharmaceutical Industries Ltd.: A leading global generic pharmaceutical company with a broad portfolio of cardiovascular drugs, including enalapril maleate.
• Viatris Inc. (formed by the merger of Mylan and Pfizer's Upjohn): Viatris offers a comprehensive range of generic medications, including enalapril maleate, serving numerous international markets.
• Hikma Pharmaceuticals PLC: A multinational pharmaceutical company specializing in generic and branded generic products. Hikma supplies enalapril maleate to markets in the U.S., Europe, and the Middle East.
• Sun Pharmaceutical Industries Ltd.: The largest pharmaceutical company in India, Sun Pharma manufactures and markets a wide array of generic drugs, including enalapril maleate.

It is important to note that enalaprilat itself is an intravenously administered drug, whereas enalapril maleate is the orally administered prodrug. The supply chain for enalaprilat (injectable) is a subset of the broader enalapril supply chain, often involving specialized sterile injectable manufacturers. Companies like Fresenius Kabi and Baxter International are significant players in the sterile injectable market and may supply enalaprilat.

What is the Intellectual Property Status of Enalaprilat?

The patent landscape for enalaprilat has largely evolved, with the foundational patents expiring decades ago. The original patent for enalapril maleate and enalaprilat was filed by Merck & Co. in the late 1970s and early 1980s.

Key IP considerations for enalaprilat:

• Original Composition of Matter Patents: The primary patents covering the enalapril molecule expired in the early 2000s. For instance, U.S. Patent 4,344,958, covering enalapril maleate, was granted in 1982.
• Evergreening Attempts: While the core patents have expired, pharmaceutical companies have historically sought to extend patent protection through secondary patents covering specific formulations, manufacturing processes, or polymorphic forms. However, for enalaprilat, significant patentable innovation beyond the original molecule is less common.
• Market Exclusivity: Regulatory exclusivity periods, such as New Chemical Entity (NCE) exclusivity, have long since passed for enalaprilat and enalapril maleate.
• Generic Competition: The expiry of primary patents has led to widespread generic competition for enalapril maleate. The injectable form, enalaprilat, also faces generic availability.
• Process Patents: While composition of matter patents are expired, patents related to novel or improved manufacturing processes for enalaprilat API may still exist. These can offer a competitive advantage to manufacturers who hold them or license them, but they do not prevent others from producing the drug using different, non-infringing processes.
• Data Exclusivity: For new product applications, data exclusivity periods can provide market protection even after patent expiry. However, enalaprilat is a well-established drug, and most current market entries are generic.

The intellectual property landscape for enalaprilat is mature. For new market entrants or investors, the focus shifts from novel patent protection to manufacturing efficiency, regulatory compliance, and market access.

How Does Enalaprilat Manufacturing Comply with Regulatory Standards?

The manufacturing of enalaprilat API and finished dosage forms is subject to rigorous regulatory oversight. Compliance with current Good Manufacturing Practices (cGMP) is mandatory.

Key regulatory compliance aspects include:

• FDA and EMA Oversight: Manufacturers selling into the U.S. and European markets must comply with FDA (21 CFR Parts 210 & 211) and EMA regulations, respectively. This includes site inspections, quality management systems, and detailed documentation.
• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies. These confidential documents provide detailed information about the manufacturing process, facilities, and quality control of the API. The FDA reviews DMFs as part of the drug product application.
• Certificates of Suitability (CEPs): European manufacturers or those targeting the European market often obtain CEPs from the European Directorate for the Quality of Medicines & HealthCare (EDQM). A CEP certifies that an API complies with the requirements of the European Pharmacopoeia.
• Quality Control and Assurance: Robust quality control testing at every stage of production, from raw materials to finished products, is essential. This includes testing for purity, potency, dissolution, and stability.
• Impurity Profiling: Regulatory agencies place significant emphasis on controlling impurities in pharmaceutical products. Manufacturers must identify, quantify, and control process-related impurities and degradation products to within acceptable limits. For enalaprilat, controlling nitrosamine impurities has been a significant regulatory focus for ACE inhibitors globally.
• Supply Chain Traceability: Ensuring the integrity and traceability of the supply chain from raw material sourcing to finished product distribution is critical to prevent counterfeiting and ensure product quality.

What are the Global Market Trends for Enalaprilat?

The market for enalaprilat and its prodrug, enalapril maleate, is largely driven by genericization and the ongoing demand for antihypertensive therapies.

Market dynamics include:

• Dominance of Generic Market: Following patent expiries, the market for enalapril maleate is dominated by generic manufacturers, leading to price competition and pressure on margins.
• Stable Demand for Injectable Enalaprilat: While less common than oral enalapril, injectable enalaprilat remains a critical therapy in hospital settings for managing hypertensive emergencies and heart failure. Demand is stable but niche compared to the oral form.
• Geographic Distribution: The largest markets for enalapril maleate are in North America and Europe, followed by emerging markets in Asia and Latin America where generic adoption is high.
• Cost-Sensitivity: Healthcare systems and payers globally favor cost-effective generic treatments, reinforcing the competitive pricing environment for enalaprilat.
• Regulatory Hurdles for New Entrants: While the IP barrier is low, new manufacturers must navigate complex regulatory approval processes in target markets, which can be time-consuming and expensive.
• Consolidation in Generic Sector: The generic pharmaceutical industry has seen significant consolidation, with larger players acquiring smaller ones to gain market share and achieve economies of scale.

Key Takeaways

The enalaprilat supply chain is characterized by a mature intellectual property landscape with expired core patents, leading to a predominantly generic market for its oral prodrug, enalapril maleate. Key API manufacturers are concentrated in India and China, with major global pharmaceutical companies supplying finished dosage forms. Regulatory compliance, particularly adherence to cGMP and impurity control, is paramount for all suppliers. The market is cost-sensitive, driven by generic competition, with stable, albeit niche, demand for injectable enalaprilat in hospital settings.

Frequently Asked Questions

1. Are there any active patents covering enalaprilat manufacturing processes? While primary composition of matter patents have expired, patents covering novel or improved manufacturing processes for enalaprilat API may still exist and could offer a competitive advantage to holders or licensees.
2. Which regulatory agencies have the most stringent requirements for enalaprilat suppliers? The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) impose the most stringent regulatory requirements, including rigorous site inspections and quality control standards.
3. What is the typical shelf life for enalaprilat API? The typical shelf life for enalaprilat API, when stored under recommended conditions, generally ranges from 2 to 5 years. Specific stability data must be confirmed with individual manufacturers.
4. How has the presence of nitrosamine impurities impacted enalaprilat manufacturers? Regulatory scrutiny over nitrosamine impurities has impacted ACE inhibitors globally. Manufacturers must implement enhanced testing and process controls to ensure that enalaprilat products remain below acceptable limits for these impurities.
5. Are there significant differences in the regulatory approval pathways for injectable enalaprilat versus oral enalapril maleate? Yes, injectable formulations require sterile manufacturing processes and more extensive stability testing, leading to distinct regulatory submission requirements compared to oral solid dosage forms.

Citations

[1] U.S. Patent 4,344,958. (1982). N-(1-(ethoxycarbonyl)-3-phenylpropyl)-L-alanyl-L-proline maleate. Retrieved from USPTO Patent Database.